6 results
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
IDSA Recommendations ... Enteric Illness: • Antimicrobial ... #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... Note: Systemic antifungals ... candida #mucosal #IDSA ... #management #opportunistic ... infections #HIVAIDS #pharmacology
Overview of antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis.
Fluconazole - Low
Overview of antifungal ... effects in the treatment ... Coccidioidomycosis #coccidioides ... #antifungals #comparison ... #table #pharmacology
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Individualized Treatment ... #antimicrobials ... #regimens #pharmacology ... drugs #steps
Antifungal agents benefits, weaknesses, and adverse effects in the treatment of Coccidioidomycosis
Fluconazole
 - Benefits: Low cost/tolerable
Antifungal agents ... effects in the treatment ... Coccidioidomycosis #pharmacology ... #management #treatment ... #coccidioides
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
IDSA Recommendations ... Disease: • CMV end-organ ... Cytomegalovirus #CMV #IDSA ... #management #opportunistic ... infections #HIVAIDS #pharmacology